Sunday, November 17, 2024 9:13:30 AM
Does not make much sense to wait for approval on GBM indication when the big pharma will be licensing combo trial for other cancer indications.
I am fairly certain that there will be no significant upfront payment to NWBO and that NWBO will be required to fund this trial themselves. Yesterday, someone here pointed to similar trick NWBO deployed in 2017 for colorectal cancer combo trial. Never got off the ground because there was no funding support. This will be similar. Another carrot they have dangled to avoid retail selling on the UK approval spike.
Besides, if big funding was coming in the next month or two and LP was confident that it would result in a significant upside in share price why would she give the option of purchasing shares at .30 cents instead of just accepting higher interest rate loan during the last financing a week or two ago. To me, thats another sign!
I am fairly certain that there will be no significant upfront payment to NWBO and that NWBO will be required to fund this trial themselves. Yesterday, someone here pointed to similar trick NWBO deployed in 2017 for colorectal cancer combo trial. Never got off the ground because there was no funding support. This will be similar. Another carrot they have dangled to avoid retail selling on the UK approval spike.
Besides, if big funding was coming in the next month or two and LP was confident that it would result in a significant upside in share price why would she give the option of purchasing shares at .30 cents instead of just accepting higher interest rate loan during the last financing a week or two ago. To me, thats another sign!
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
